Home Tags Cancer

Tag: cancer

Early Detection: The New Cancer Paradigm

A seemingly healthy patient walks into the doctor’s office for a routine checkup. The doctor says: "I have good news and bad news.  The...

Sneaking Medicines Across the Blood-Brain Barrier

Research published in the November 2014 edition of The FASEB Journal, published by the Federation of the American Societies for Experimental Biology, suggests that a very small single domain antibody called FC5 has proven able to cross the blood-brain barrier (BBB). This opens the door to new treatments for a multitude of brain diseases.
Chronic Lymphocytic Leukemia

Novel IgM-derived Antibody-drug Conjugate Targets Fcμ-receptor in Chronic Lymphocytic Leukemia

Chronic lymphocytic leukemia or CLL, one of the most common forms of leukemia in Europe and North America, is a disorder of morphologically mature...

NRC and AvidBiologics Progress In Development of New Antibody-drug Conjugates

Antibody-drug conjugates combine the targeting attributes of antibodies with the cancer destroying properties of drugs that are toxic to cells. Unlike chemotherapy, antibody-drug conjugates specifically seek and destroy cancer cells, with minimal impact on healthy cells.

Study Confirms DMOT4039A Shows Anticancer Activity in Patients with Pancreatic or...

A study presented at the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO) being held May 30 - June 3, 2014 in Chicago, Ill, describes the results of a phase I clinical trial of the investigational agent DMOT4039A against pancreatic and ovarian cancers. In this early clinical trial with the goal of identifying possible risks and defining likely dosages, the drug was well tolerated and in some patients showed initial evidence of anti-cancer activity.

Phase II PRECEDENT Trial of Vintafolide in Platinum-Resistant Ovarian Cancer Basis...

Based on trial results from the randomized Phase II PRECEDENT trial for vintafolide (MK-8109/EC145; Merck and Endocyte), an investigational folate small molecule drug conjugate or SMDC, published in the Journal of Clinical Oncology (JCO), the official journal of the American Society of Clinical Oncology, a regulatory application is currently under review with the European Medicines Agency for the treatment of folate-receptor positive platinum-resistant ovarian cancer in combination with pegylated liposomal doxorubicin (PLD).

Investigational Drug MLN0264 May Provide New Treatment Option for Pancreatic Cancer...

Patients with pancreatic cancer may benefit from MLN0264, an investigational member of an emerging class of anticancer drugs called antibody-drug conjugates or ADCs. Preclinical results of MLN0264 were presented at the International Conference on Molecular Targets and Cancer Therapeutics, held in the Hynes Convention Center in Boston, Massachusetts, USA, October 19-23, 2013
CPhl worldwide

CPhI Report Sees ADCs as a Key Driver of Tomorrow’s Healthcare

In the first section of the 2013 annual report and industry expert panel, analysts at CPhI Worldwide and CPhI Pharma Evolution describe how they expect that antibody-drug conjugates or ADCs will become a major product group within the oncology market.

AMF-1c-120 Targets and Binds to Tumors in a Very Localized and...

Results of recent pre-clinical studies with AMF-1c-120 (Amorfix Life Sciences, Ltd) shows that this proprietary anti-ovarian cancer antibody, when administered to live animals, targets and binds to tumors in a very localized and concentrated manner. This is a significant finding because it shows that the antibody retains its tumor-specific binding in vivo.

Clinical Trial with Inotuzumab Ozogamicin in Relapsed or Refractory Aggressive Non-Hodgkin...

Earlier today, Pfizer Inc. confirmed that it had discontinued a Phase III randomized, open-label, two-arm study (B1931008) evaluating the safety and efficacy of the...